Key Developments: Synergy Pharmaceuticals Inc (SGYP.O)
5.30USD
17 May 2013
$0.21 (+4.13%)
$5.09
$5.10
$5.45
$5.00
3,432,666
975,300
$7.44
$2.98
Latest Key Developments (Source: Significant Developments)
Synergy Pharmaceuticals Inc Announces Full Exercise Of Over-Allotment Option
Synergy Pharmaceuticals Inc announced the full exercise of the over-allotment option granted to the underwriters to purchase 281,250 additional units, at a public offering price of $8.00 per unit, in connection with its previously announced underwritten public offering of 1,875,000 units, bringing total gross proceeds from the offering to $17,250,000. The warrants will be exercisable at an exercise price of $5.50 per share upon separation of the units and will expire on December 6, 2016. Aegis Capital Corp. acted as the sole book-running manager and EarlyBirdCapital, Inc. acted as co-manager for the offering. Full Article
Synergy Pharmaceuticals Inc Files Suit Against Ironwood Pharmaceuticals, Inc. And Its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Synergy Pharmaceuticals Inc announced that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc., and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading. In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages. Full Article
Synergy Pharmaceuticals Inc Announces Closing of Public Offering of 1,875,000 Units
Synergy Pharmaceuticals Inc announced the closing of its underwritten public offering of 1,875,000 units at an offering price of $8.00 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The common stock and warrants will not be separately transferable until the earlier of the exercise in full of the underwriters' overallotment option or January 15, 2012. Each warrant will have an exercise price of $5.50 per share, will be exercisable upon separation of the units and will expire five years from the date of issuance. When separately transferable, the warrants will trade on The NASDAQ Capital Market under the symbol "SGYPW". Synergy received net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $13.97 million. Synergy has also granted the underwriters a 45-day option to purchase up to an additional 281,250 units to cover over-allotments, if any. Full Article
Synergy Pharmaceuticals Inc Raises $5.64 Million In Financing
Synergy Pharmaceuticals Inc announced that it has completed a financing in which it raised gross proceeds of approximately $5.648 million through the sale of 2,657,882 units, each unit consisting of one share of common stock and one common stock purchase warrant, at a purchase price of $2.125 per unit. The warrants are immediately exercisable at an exercise price of $2.75 per share and are exercisable for five years. The proceeds from the financing will be used for working capital, to advance clinical development of plecanatide and to bring SP-333, Synergy’s second-generation GC-C receptor analog into the clinic. Full Article
BRIEF-Synergy Pharmaceuticals shares off 6 pct premarket
NEW YORK, April 11 - Synergy Pharmaceuticals Inc : * Shares off 6 percent premarket after pricing of stock offering
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
